Race On: China Starts Coronavirus Vaccine Trial, Vows Fast Development
The Race For Covid-19 Vaccines Is Hotting Up
Executive Summary
Leveraging on its Ebola vaccine success, Tianjin-based CanSino is testing its vaccine on humans in Wuhan and hopes to get China’s first COVID-19 vaccine on the market soon.
You may also be interested in...
When The Mighty Fall, Smaller Vaccine Players Seize The COVID Day
While global vaccine heavyweights such as Merck & Co, Sanofi and GSK have somewhat lagged in the development of vaccines for COVID-19, smaller players have stepped up. This is especially true for highly segmented markets such as China, where agility has been important.
How COVID-19 Defined 2020 For Biopharma
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
Bharat, UW-Madison, FluGen Pursue Intranasal COVID-19 Vaccine
Bharat Biotech has joined hands with University of Wisconsin–Madison and US-based FluGen to develop a nasal vaccine against COVID-19, becoming one of only two entities taking the intranasal, more convenient route of administration. Separately, Bharat's chikungunya vaccine is expected to enter Phase III by December 2020.